Naturalendo Tech Co., Ltd. (KOSDAQ:168330)
2,800.00
+125.00 (4.67%)
At close: Jan 27, 2026
Naturalendo Tech Revenue
Naturalendo Tech had revenue of 5.75B KRW in the quarter ending September 30, 2025, a decrease of -10.96%. This brings the company's revenue in the last twelve months to 21.87B, down -8.98% year-over-year. In the year 2024, Naturalendo Tech had annual revenue of 22.26B with 18.48% growth.
Revenue (ttm)
21.87B
Revenue Growth
-8.98%
P/S Ratio
3.93
Revenue / Employee
270.06M
Employees
81
Market Cap
86.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22.26B | 3.47B | 18.48% |
| Dec 31, 2023 | 18.79B | 4.84B | 34.69% |
| Dec 31, 2022 | 13.95B | -744.85M | -5.07% |
| Dec 31, 2021 | 14.70B | 1.45B | 10.93% |
| Dec 31, 2020 | 13.25B | 6.67B | 101.31% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 132.76B |
| KoBioLabs | 71.83B |
| Cell Biotech | 50.65B |
| Choong Ang Vaccine Laboratory | 39.19B |
| PanGen Biotech | 15.27B |
| HLB Pep | 4.89B |
| Quratis | 2.28B |
| Progen | 450.00M |